Fatty acids - Good for the brain, good for Alzheimer disease

September 08, 2005

EDITOR'S PICK

A number of studies suggest a protective action of the fatty acid DHA in cognitive decline and in Alzheimer disease (AD). However, the molecular mechanism is not understood. In a paper appearing online on September 8 in advance of print publication of the October 1 issue of the Journal of Clinical Investigation, Nicolas Bazan and colleagues from Louisiana State University identify a specific mechanism by which DHA is neuroprotective in AD.

The authors report that DHA can decrease levels of the pathogenic Abeta peptides that are associated with Alzheimer disease pathology in human brain cells. Meanwhile, the synthesis of neuroprotectin D1 (NPD1), an endogenous DHA-derived messenger, is upregulated. NPD1 inhibits apoptosis triggered by Abeta peptides. In a human AD donor brain, the authors show that DHA and NPD1 are reduced in vulnerable brain regions.

This data raises the possibility that NPD1 is a key regulator of cell survival, and might be manipulated for the development of novel therapeutic strategies for neurodegenerative diseases.
-end-
TITLE:A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease

AUTHOR CONTACTS:
(1) Nicolas Bazan
LSU Neuroscience Center of Excellence, New Orleans, LA USA
Phone: 504-599-0831; Fax: 504-568-5801; E-mail: nbazan@lsuhsc.edu

(2) Charles N. Serhan
Brigham and Women's Hospital, Boston, MA USA
Phone: 617-732-8822; Fax: 617-278-6957; E-mail: cnserhan@zeus.bwh.harvard.edu

View the PDF of this article at: https://www.the-jci.org/article.php?id=25420

JCI Journals

Related Alzheimer Disease Articles from Brightsurf:

Potential link for Alzheimer's disease and common brain disease that mimics its symptoms
A new study by investigators from Brigham and Women's Hospital uncovered a group of closely related genes that may capture molecular links between Alzheimer's disease and Limbic-predominant Age-related TDP-43 Encephalopathy, or LATE, a recently recognized common brain disorder that can mimic Alzheimer's symptoms.

Uncovering Alzheimer's disease
Characterized by a buildup of amyloid plaques in the brain, Alzheimer's is an irreversible disease that leads to memory loss and a decrease in cognitive function.

Viewpoint: Could disease pathogens be the dark matter behind Alzheimer's disease?
In a lively discussion appearing in the Viewpoint section of the journal Nature Reviews Neurology, Ben Readhead, a researcher in the ASU-Banner Neurodegenerative Disease Research Center at the Biodesign Institute joins several distinguished colleagues to discuss the idea that bacteria, viruses or other infectious pathogens may play a role in Alzheimer's disease.

Coordination chemistry and Alzheimer's disease
It has become evident recently that the interactions between copper and amyloid-╬▓ neurotoxically impact the brain of patients with Alzheimer's disease.

How Alzheimer's disease spreads through the brain
Tau can quickly spread between neurons but is not immediately harmful, according to research in mouse neurons published in JNeurosci.

A protective factor against Alzheimer's disease?
Researchers at the German Center for Neurodegenerative Diseases (DZNE) and the Institute for Stroke and Dementia Research (ISD) at the University Hospital of the Ludwig-Maximilians-Universit├Ąt (LMU) in Munich have found that a protein called TREM2 could positively influence the course of Alzheimer's disease.

An alternate theory for what causes Alzheimer's disease
Alzheimer's disease, the most common cause of dementia among the elderly, is characterized by plaques and tangles in the brain, with most efforts at finding a cure focused on these abnormal structures.

Alzheimer's: How does the brain change over the course of the disease?
What changes in the brain are caused by Alzheimer's disease?

Possible pathway to new therapy for Alzheimer's disease
Researchers have uncovered an enzyme and a biochemical pathway they believe may lead to the identification of drugs that could inhibit the production of beta-amyloid protein, the toxic initiator of Alzheimer's disease (AD).

Promising novel treatment against Alzheimer disease
New research conducted at the Lady Davis Institute (LDI) at the Jewish General Hospital reveals that a novel drug reverses memory deficits and stops Alzheimer disease pathology (AD) in an animal model.

Read More: Alzheimer Disease News and Alzheimer Disease Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.